Jubilant Pharmova to Transfer API Business to Subsidiary Jubilant Biosys

MT Newswires Live

2025/06/13

Jubilant Pharmova (NSE:JUBLPHARMA, BOM:530019) said its board has approved the transfer of its Active Pharmaceutical Ingredients (API) business to its wholly owned subsidiary Jubilant Biosys on a slump sale basis, according to a Thursday filing.

The transaction is expected to be completed by Sept. 1, subject to approvals from lenders and shareholders.

The consideration, yet to be finalized, will primarily be settled through share issuance under the terms of the business transfer agreement, the company said in the filing.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2543687960"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2543687960\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2543687960?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-06-13 21:11","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2543687960","market":"sh","top_or_hot":-1,"title":"Jubilant Pharmova to Transfer API Business to Subsidiary Jubilant Biosys","media":"MT Newswires Live","content":"<html><body><p> Jubilant Pharmova (NSE:JUBLPHARMA, BOM:530019) said its board has approved the transfer of its Active Pharmaceutical Ingredients (API) business to its wholly owned subsidiary Jubilant Biosys on a slump sale basis, according to a Thursday filing.</p><p>The transaction is expected to be completed by Sept. 1, subject to approvals from lenders and shareholders.</p><p>The consideration, yet to be finalized, will primarily be settled through share issuance under the terms of the business transfer agreement, the company said in the filing.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Jubilant Pharmova to Transfer API Business to Subsidiary Jubilant Biosys</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nJubilant Pharmova to Transfer API Business to Subsidiary Jubilant Biosys\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2025-06-13 21:11</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Jubilant Pharmova (NSE:JUBLPHARMA, BOM:530019) said its board has approved the transfer of its Active Pharmaceutical Ingredients (API) business to its wholly owned subsidiary Jubilant Biosys on a slump sale basis, according to a Thursday filing.</p><p>The transaction is expected to be completed by Sept. 1, subject to approvals from lenders and shareholders.</p><p>The consideration, yet to be finalized, will primarily be settled through share issuance under the terms of the business transfer agreement, the company said in the filing.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"OTX.SI","symbol_name":"迈怡汇有限公司","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2543687960","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2543687960","pubTimestamp":1749820293,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Jubilant Pharmova  said its board has approved the transfer of its Active Pharmaceutical Ingredients  business to its wholly owned subsidiary Jubilant Biosys on a slump sale basis, according to a Thursday filing.The transaction is expected to be completed by Sept. 1, subject to approvals from lenders and shareholders.The consideration, yet to be finalized, will primarily be settled through share issuance under the terms of the business transfer agreement, the company said in the filing.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"OTX.SI":"迈怡汇有限公司","BK4535":"淡马锡持仓","API":"声网","BK4503":"景林资产持仓","API.AU":"Australian Pharma Industries","BK4551":"寇图资本持仓","BK7103":"保健护理产品经销商","BK4023":"应用软件"},"translate_title":"Jubilant Pharmova将API业务转让给子公司Jubilant Biosys","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"API":1,"API.AU":1,"OTX.SI":1},"content_text":"Jubilant Pharmova (NSE:JUBLPHARMA, BOM:530019) said its board has approved the transfer of its Active Pharmaceutical Ingredients (API) business to its wholly owned subsidiary Jubilant Biosys on a slump sale basis, according to a Thursday filing.The transaction is expected to be completed by Sept. 1, subject to approvals from lenders and shareholders.The consideration, yet to be finalized, will primarily be settled through share issuance under the terms of the business transfer agreement, the company said in the filing.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}